Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Pliant Therapeutics in a report released on Monday, February 10th. HC Wainwright analyst E. Arce ...

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been given an average rating of “Hold” by the eleven analysts that are presently covering the company, Marketbeat reports.

By Priyanjana Pramanik, MSc. A national poll reveals that while health challenges can hold some older adults back from ...

By Tarun Sai Lomte A four-week treatment with oral vancomycin led to clinical remission in PSC-IBD patients, accompanied by ...

An antibiotic used to treat infective diarrhoea may be an effective drug for a type of inflammatory bowel disease, according ...

Researchers have found in a new study that common antibiotic Vancomycin may also be effective in treating individuals with a ...

Canaccord Genuity has downgraded Pliant (PLRX) to hold following news that the company has paused a clinical trial for its ...

A study led by the University of Birmingham found that vancomycin, a commonly used antibiotic for diarrhea, could effectively ...

An antibiotic used to treat infective diarrhoea could be an effective drug for a type of inflammatory bowel disease, a new study has found.

Results published in the Journal of Crohn's and Colitis revealed that an antibiotic called vancomycin may also be effective ...

Pliant Therapeutics, Inc. (NASDAQ:PLRX) stock is trading lower on Monday. On Friday, during after-hours trading, Pliant ...